4/A: Pulmonx Corp Executive Rose Geoffrey Beran Amends SEC Filing to Correct Stock Option and RSU Details

An amended SEC filing reveals corrections to the number of shares underlying employee stock options and restricted stock units (RSUs) previously reported by Pulmonx Corp's Chief Commercial Officer, Rose Geoffrey Beran.

Summary

• Rose Geoffrey Beran, Chief Commercial Officer of Pulmonx Corp, filed an amendment to a previous SEC Form 4.
• The amendment corrects typographical errors in the number of shares underlying the Employee Stock Option and Restricted Stock Units (RSUs) as reported in the original filing on March 5, 2024.
• The corrected filing shows that on March 1, 2024, Beran was granted 69,100 RSUs that vest over four years in equal quarterly installments.
• Beran was also granted an option to buy 34,500 shares of common stock at an exercise price of $9.30, vesting in 48 equal monthly installments beginning on March 1, 2024.
• Following these transactions, Beran beneficially owns 309,052 shares of common stock and options for 34,500 shares.
• The options expire on February 28, 2034.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting minor errors. It doesn't contain information that would significantly impact investor sentiment positively or negatively. The sentiment is neutral to slightly positive due to increased transparency.

Positives

• The amendment provides accurate information regarding the executive's stock options and RSU grants.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of key executives, which is a common practice in the industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded companies, particularly in the biotech and medical device industries where Pulmonx operates.
• Companies like Medtronic, Boston Scientific, and Stryker also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders benefit from accurate and transparent reporting of executive compensation.
• Employees, particularly executives, are directly impacted by the terms of their equity compensation.

Key Dates